138 related articles for article (PubMed ID: 10707873)
1. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M
J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 in the treatment of chronic hepatitis B and C.
Zeuzem S; Carreño V
Antiviral Res; 2001 Nov; 52(2):181-8. PubMed ID: 11672828
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
[TBL] [Abstract][Full Text] [Related]
11. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
Teuber G; Rossol S; Lee JH; Dietrich CF; Zeuzem S
Z Gastroenterol; 2002 Jul; 40(7):487-95. PubMed ID: 12122596
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
14. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
Schreiber S; Fedorak RN; Nielsen OH; Wild G; Williams CN; Nikolaus S; Jacyna M; Lashner BA; Gangl A; Rutgeerts P; Isaacs K; van Deventer SJ; Koningsberger JC; Cohard M; LeBeaut A; Hanauer SB
Gastroenterology; 2000 Dec; 119(6):1461-72. PubMed ID: 11113067
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
Zavaglia C; Severini R; Tinelli C; Franzone JS; Airoldi A; Tempini S; Bettale G; Ideo G
Dig Dis Sci; 2000 Apr; 45(4):690-6. PubMed ID: 10759236
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
Fedorak RN; Gangl A; Elson CO; Rutgeerts P; Schreiber S; Wild G; Hanauer SB; Kilian A; Cohard M; LeBeaut A; Feagan B
Gastroenterology; 2000 Dec; 119(6):1473-82. PubMed ID: 11113068
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
